Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the I...

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core  ACS Publications

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC - OncLive

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC  OncLive

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting  ASCO Daily News

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resist...

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib  Nature

Nuvalent Launches Head-to-Head Phase 3 Trial Against Leading Lung Cancer Drug, Plus New HER2 Stud...

Nuvalent Launches Head-to-Head Phase 3 Trial Against Leading Lung Cancer Drug, Plus New HER2 Study  Stock Titan

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports - Fron...

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports  Frontiers

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment f...

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer  Roche

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - Cancer Network

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  Cancer Network

FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)

FDA Approves Alectinib for ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Sequencing and Management Considerations for ALK TKIs in NSCLC - Targeted Oncology

Sequencing and Management Considerations for ALK TKIs in NSCLC  Targeted Oncology

Successful treatment of a non-small-cell lung cancer patient harboring HIP1-ALK (H28:A20) and CTN...

Successful treatment of a non-small-cell lung cancer patient harboring HIP1-ALK (H28:A20) and CTNNB1 p.S45del with alectinib  Wiley Online Library

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the I...

Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core  ACS Publications

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in ...

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient  Frontiers

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-pos...

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer  Nature

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangeme...

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review | JCO Precision Oncology  ASCO Publications

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy i...

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement  Frontiers

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC - Fro...

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC  Frontiers

Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarci...

Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review  Frontiers

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and litera...

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and literature review  Frontiers

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in ...

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib  Wiley Online Library

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive...

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive NSCLC  The ASCO Post

Fig 1: Inhibitory role of Alectinib on EML4-ALK positive NSCLC and... - ResearchGate

Fig 1: Inhibitory role of Alectinib on EML4-ALK positive NSCLC and...  ResearchGate

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in ...

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib  Wiley Online Library

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer - PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer  PMLiVE

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC - Oncol...

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC  Oncology Nursing News

Alectinib “First of Many Approvals” In ALK+ NSCLC - Cancer Network

Alectinib “First of Many Approvals” In ALK+ NSCLC  Cancer Network

FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC - OncLive

FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC  OncLive

Hypersensitivity in ALK-positive lung cancers - ResearchGate

Hypersensitivity in ALK-positive lung cancers  ResearchGate

Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for peo...

Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for people with ALK-positive early-stage lung cancer  Newswire.ca

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - OncLive

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC  OncLive

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicent...

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study  BMC Medicine

CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC - Targeted Oncology

CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC  Targeted Oncology

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Instit...

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-posit...

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer  Wiley Online Library

Eosin‐5‐maleimide (EMA) binding study results of the patient receiving... - ResearchGate

Eosin‐5‐maleimide (EMA) binding study results of the patient receiving...  ResearchGate

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature

Adjuvant Alectinib Gets FDA Priority Review for Early-Stage ALK+ NSCLC - Oncology Nursing News

Adjuvant Alectinib Gets FDA Priority Review for Early-Stage ALK+ NSCLC  Oncology Nursing News

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy ...

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib  Cancer Therapy Advisor

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial - MedPage Today

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial  MedPage Today

Chemical structure of alectinib, an ALK inhibitor. - ResearchGate

Chemical structure of alectinib, an ALK inhibitor.  ResearchGate

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - The New Engla...

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature

FDA Approves Adjuvant Alectinib in ALK+ NSCLC - Targeted Oncology

FDA Approves Adjuvant Alectinib in ALK+ NSCLC  Targeted Oncology

High incidence and reversible bradycardia events following alectinib initiation - Yuan - 2023 - T...

High incidence and reversible bradycardia events following alectinib initiation - Yuan - 2023 - Thoracic Cancer  Wiley Online Library

Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape

Alectinib Approved for ALK-Positive Adjuvant NSCLC  Medscape

The Downfall of Consolidation Immunotherapy and Rise of Targeted Therapy in Unresectable Stage II...

The Downfall of Consolidation Immunotherapy and Rise of Targeted Therapy in Unresectable Stage III NSCLC With EGFR and ALK Alterations  ASCO Daily News

In CROWN, Lorlatinib Shows Longest PFS in ALK-Positive Lung Cancer - MedPage Today

In CROWN, Lorlatinib Shows Longest PFS in ALK-Positive Lung Cancer  MedPage Today

Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC - AJMC

Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC  AJMC

Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell ly...

Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial  Wiley Online Library

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision...

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision Oncology  Nature

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC - Oncology Nursing News

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC  Oncology Nursing News

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - MedPage Today

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC  MedPage Today

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers - Cancer Therapy Ad...

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers  Cancer Therapy Advisor

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Na...

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer  Nature

Treatment Options for Patients with ALK+ NSCLC who Progress on First-line TKIs - Targeted Oncology

Treatment Options for Patients with ALK+ NSCLC who Progress on First-line TKIs  Targeted Oncology

Cancer drug alectinib less effective when taken with low-fat yogurt - Healio

Cancer drug alectinib less effective when taken with low-fat yogurt  Healio

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage...

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC  OncLive

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK ...

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK -positive non-small-cell lung cancer  Wiley Online Library

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 - Nature

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1  Nature

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-sm...

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer  Wiley Online Library

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable...

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer  Frontiers

Alectinib Approved for ALK-Positive NSCLC - National Cancer Institute (.gov)

Alectinib Approved for ALK-Positive NSCLC  National Cancer Institute (.gov)

Adjuvant alectinib improves disease-free survival in lung cancer - Medical Xpress

Adjuvant alectinib improves disease-free survival in lung cancer  Medical Xpress

Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine

Diet May Have Big Effect on Common Lung Cancer Treatment  Inside Precision Medicine

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-sma...

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer  Frontiers

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an...

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial  The Lancet

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type o...

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer  Roche

Roche wins second FDA label expansion for Alecensa in NSCLC - Pharmaceutical Technology

Roche wins second FDA label expansion for Alecensa in NSCLC  Pharmaceutical Technology

Schema for ALNEO trial and NAUTIKA1 trial. Abbreviations: ALK =... - ResearchGate

Schema for ALNEO trial and NAUTIKA1 trial. Abbreviations: ALK =...  ResearchGate

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive cr...

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China  Frontiers

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lun...

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis  Frontiers

NICE recommendation for ALK-positive lung cancer - Pf Media

NICE recommendation for ALK-positive lung cancer  Pf Media

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resou...

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings  Nature

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative r...

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib - Matsumura - 2021 - Thoracic Cancer  Wiley Online Library

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC - Medscape

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC  Medscape

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometr...

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging  Nature

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK pos...

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)  Frontiers

ALK fusions in the pan-cancer setting: another tumor-agnostic target? - Nature

ALK fusions in the pan-cancer setting: another tumor-agnostic target?  Nature

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A ...

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report  Frontiers

Roche Korea’s ALK-positive lung cancer drug gets expanded indication - koreabiomed.com

Roche Korea’s ALK-positive lung cancer drug gets expanded indication  koreabiomed.com

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and liter...

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review  Frontiers

Alectinib (Alecensa) - Oncology Nurse Advisor

Alectinib (Alecensa)  Oncology Nurse Advisor

Roche's Alecensa gains EU approval for ALK-positive early-stage lung cancer - FirstWord Pharma

Roche's Alecensa gains EU approval for ALK-positive early-stage lung cancer  FirstWord Pharma

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, c...

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation  Frontiers

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiothe...

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib  Frontiers

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring ...

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion  Frontiers

Density Functional Theory and Raman Spectroscopy Studies of Adsorption Sites of Au Nanoparticles ...

Density Functional Theory and Raman Spectroscopy Studies of Adsorption Sites of Au Nanoparticles with Alectinib  ACS Publications

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo...

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo and ex vivo  Nature

NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy - Targeted Oncology

NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy  Targeted Oncology

Inhibition of Anaplastic Lymphoma Kinase Protects From Ischemic Stroke - American Heart Associati...

Inhibition of Anaplastic Lymphoma Kinase Protects From Ischemic Stroke  American Heart Association Journals

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lun...

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer  ASCO Daily News

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with E...

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports  Frontiers

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alect...

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib  Wiley Online Library

Targeted cancer drug during pregnancy - VUMC News

Targeted cancer drug during pregnancy  VUMC News